Literature DB >> 21510948

Orexin/hypocretin receptor chimaeras reveal structural features important for orexin peptide distinction.

Jaana Putula1, Pauli M Turunen, Lisa Johansson, Johnny Näsman, Runar Ra, Laura Korhonen, Jyrki P Kukkonen.   

Abstract

We wanted to analyze the basis for the distinction between OX(1) and OX(2) orexin receptors by the known agonists, orexin-A, orexin-B and Ala(11), D-Leu(15)-orexin-B, of which the latter two show some selectivity for OX(2). For this, chimaeric OX(1)/OX(2) and OX(2)/OX(1) orexin receptors were generated. The receptors were transiently expressed in HEK-293 cells, and potencies of the agonists to elicit cytosolic Ca(2+) elevation were measured. The results show that the N-terminal regions of the receptor are most important, and the exchange of the area from the C-terminal part of the transmembrane helix 2 to the transmembrane helix 4 is enough to lead to an almost total change of the receptor's ligand profile.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21510948     DOI: 10.1016/j.febslet.2011.04.020

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

Review 1.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

2.  Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery.

Authors:  Jaana Putula; Tero Pihlajamaa; Jyrki P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-11-05       Impact factor: 8.739

3.  Truncated Orexin Peptides: Structure-Activity Relationship Studies.

Authors:  Nadezhda A German; Ann M Decker; Brian P Gilmour; Brian F Thomas; Yanan Zhang
Journal:  ACS Med Chem Lett       Date:  2013-12-12       Impact factor: 4.345

Review 4.  OX1 and OX2 orexin/hypocretin receptor pharmacogenetics.

Authors:  Miles D Thompson; Henri Xhaard; Takeshi Sakurai; Innocenzo Rainero; Jyrki P Kukkonen
Journal:  Front Neurosci       Date:  2014-05-06       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.